TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nursing home operators report that more residents are arriving on GLP-1 medications, now used for conditions beyond diabetes and weight loss. Providers say the drugs may offer health benefits but require careful monitoring, while coverage gaps and facility costs remain unresolved. A temporary Medicare Part D bridge program is extended through 2027; a more permanent program has been delayed without a new start date.
GLP-1 medications are becoming more common among nursing home residents, according to operators and post-acute care specialists, bringing new demands for clinical monitoring and renewed questions over who pays for the drugs. At New Jersey-based Venza Care, about 30% to 40% of new admissions are taking a GLP-1, Chief Nursing Officer Lisa Chubb told Skilled Nursing News, while Medicare’s temporary coverage arrangement has been extended through 2027 and a planned permanent program remains delayed.
Chubb said incoming residents are now taking GLP-1s for purposes beyond diabetes and weight loss, including what she described as prevention or management related to cardiovascular conditions, metabolic health and organ health. The share is higher at facilities with more short-stay residents, she said. The report does not provide an industry-wide estimate, so Venza’s figures should not be read as representative of all nursing homes.
At Venza, interdisciplinary teams discuss residents at weekly “nutrition at risk” meetings. Chubb said the operator uses electronic health record assessments to document medication review and education, and tracks residents’ weight. Registered dietitians also take part in care for residents using the drugs. Providers must weigh potential benefits against risks for older adults who may already be frail or vulnerable to muscle weakness and further weight loss.
Payment depends in part on a resident’s coverage and the medication’s eligibility. Jessie McGill, a senior curriculum development specialist at the American Association for Post-Acute Care Nursing (AAPACN), said the Medicare Part D bridge program covers certain GLP-1s prescribed for weight loss, with a $50 monthly fee in addition to Part D coverage. She said the eligible drugs are Wegovy, Zepbound and Foundeo. The program does not remove all costs, and some residents may struggle to pay the fee. For residents covered under Medicare Part A, the nursing home may be responsible for the medication cost, McGill said.
Care Plans and Facility Budgets
Growing use could affect both resident care and nursing home finances. Staff may need to document medication use, monitor nutrition and weight changes, and respond to side effects, while facilities face decisions about whether they can absorb high drug costs. Those pressures can be especially difficult when residents have limited income or when coverage does not apply to a particular prescription.
Jody O’Mara, chief nursing officer for Journey Skilled Nursing, said the medications could alter facility assessments, the residents operators accept and quality-assurance programs. She said her organization was discussing a pharmacy-services joint venture for residents in Georgia and viewed the potential benefits as outweighing the cost. That is an operator’s assessment, not a settled finding about the drugs’ value for every nursing home resident.
The clinical trade-off is also different from weight management in younger, healthier populations. A resident who is already frail or losing muscle may not benefit from additional weight loss. Care teams need to consider an individual’s health, goals, nutritional status and ability to tolerate treatment rather than treating weight change as an uncomplicated measure of success.
Products Worth Considering
Levoit EverestAir-P Smart Air Purifier for Large Rooms
Levoit Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft²
Levoit Vital Pet Pro Smart Air Purifier for Pets, White
As an affiliate, we earn on qualifying purchases.
Temporary Medicare Drug Coverage
The coverage arrangement described by AAPACN is a bridge program under Medicare Part D. It can cover certain GLP-1 prescriptions for weight loss when the resident has not already been prescribed a GLP-1 for diabetes, which McGill said is covered under Part D. Eligibility also involves criteria related to body mass index and other chronic conditions. The source report says the bridge program is extended through 2027.
A more permanent program known as BALANCE has been delayed, with no future implementation date stated in the report. McGill said residents on Medicare Part A can leave facilities responsible for a GLP-1 expense, particularly if the drug is not eligible for the bridge arrangement. She said expanding Medicare consolidated billing to cover high-cost drugs such as GLP-1s would be one possible way to address costs. The report identifies that as a policy proposal, not a change already adopted.
The report also highlights the clinical difference between nursing home residents and the populations often discussed in connection with GLP-1s. Older residents may have frailty, multiple chronic conditions, nutritional risks and functional limitations, which can change how clinicians judge likely benefits and potential harms.
“We see a lot of our new admissions coming in with GLP-1s. Initially it was used solely for weight loss and diabetes, but now we’re seeing it trend in other directions as well.”
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Resident Risks
The report does not establish how widespread GLP-1 use is across nursing homes nationally, or how many residents are covered through the bridge program. Venza’s admission figures are specific to that operator. It is also unclear when BALANCE could begin, whether the program’s terms will change, or whether Congress will act on the proposed expansion of consolidated billing.
Clinical outcomes for nursing home residents are not quantified in the source report. Providers raise concerns about frailty, muscle weakness, nutrition and possible side effects including nausea, vomiting, constipation and dehydration, but the report does not give rates for these events or compare outcomes among residents. Individual prescribing decisions and the balance of benefit and risk remain dependent on each resident’s circumstances.
Monitoring Policy and Care Changes
For now, providers will continue managing residents under the bridge program extended through 2027, while weighing medication coverage against Part A costs and residents’ ability to pay. Facilities described in the report are adding medication review, staff education, nutrition monitoring and interdisciplinary discussion to their care processes.
The next policy milestone is uncertain: the report gives no new implementation date for BALANCE. A change to consolidated billing would require further action, and McGill’s comments describe a possible route rather than an enacted policy. Nursing home operators and residents will need clearer coverage terms to know how drug costs will be divided and whether facilities will take on more prescriptions.
As use grows, the practical test for providers will be how to make individualized treatment decisions while tracking nutrition, function, side effects and spending. The available reporting describes an emerging operational challenge, but does not yet establish how the medications affect outcomes across nursing home populations.
Key Questions
How common are GLP-1 medications among nursing home residents?
Venza Care’s Lisa Chubb said about 30% to 40% of new admissions at her organization are taking GLP-1s, with higher shares at facilities that have more short-stay residents. The report does not provide a national estimate.
What does the Medicare Part D bridge program cover?
AAPACN’s Jessie McGill said the program covers certain GLP-1s for weight loss for eligible residents, with a $50 monthly fee in addition to Part D coverage. She named Wegovy, Zepbound and Foundeo as eligible drugs. The report says the bridge program is extended through 2027.
Who may pay for a resident’s GLP-1 in a nursing home?
Payment depends on the resident’s coverage and whether the prescription qualifies for the bridge program. McGill said a nursing home may be responsible for costs for residents on Medicare Part A, while Part D coverage may still leave residents facing fees or other expenses.
Why do clinicians have concerns about GLP-1 use in older residents?
Nursing home residents may already have frailty, nutritional concerns, chronic conditions or limits in daily function. AAPACN’s Lauren Stenson cited possible nausea, vomiting, constipation and dehydration; providers also say weight loss and muscle weakness require careful monitoring.
When will the permanent BALANCE program begin?
The source report says BALANCE has been delayed and provides no future implementation date. The temporary bridge program is extended through 2027, but its continuation does not set a start date for BALANCE.
Source: skillednursingnews.com
